Ipriflavone (Osteofix)CAS# 35212-22-7 |
- A-867744
Catalog No.:BCC1324
CAS No.:1000279-69-5
- Rocuronium Bromide
Catalog No.:BCC1068
CAS No.:119302-91-9
- Rivastigmine
Catalog No.:BCC1900
CAS No.:123441-03-2
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 35212-22-7 | SDF | Download SDF |
PubChem ID | 3747 | Appearance | Powder |
Formula | C18H16O3 | M.Wt | 280.32 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : ≥ 29 mg/mL (103.45 mM) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | 3-phenyl-7-propan-2-yloxychromen-4-one | ||
SMILES | CC(C)OC1=CC2=C(C=C1)C(=O)C(=CO2)C3=CC=CC=C3 | ||
Standard InChIKey | SFBODOKJTYAUCM-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C18H16O3/c1-12(2)21-14-8-9-15-17(10-14)20-11-16(18(15)19)13-6-4-3-5-7-13/h3-12H,1-2H3 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Ipriflavone (Osteofix) Dilution Calculator
Ipriflavone (Osteofix) Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.5674 mL | 17.8368 mL | 35.6735 mL | 71.347 mL | 89.1838 mL |
5 mM | 0.7135 mL | 3.5674 mL | 7.1347 mL | 14.2694 mL | 17.8368 mL |
10 mM | 0.3567 mL | 1.7837 mL | 3.5674 mL | 7.1347 mL | 8.9184 mL |
50 mM | 0.0713 mL | 0.3567 mL | 0.7135 mL | 1.4269 mL | 1.7837 mL |
100 mM | 0.0357 mL | 0.1784 mL | 0.3567 mL | 0.7135 mL | 0.8918 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Ipriflavone is a synthetic isoflavone derivative used to suppress bone resorption.
In Vitro:Ipriflavone inhibits the proliferation and DNA synthesis of MDA-231 cells and blocks the ligand-induced phosphorylation of Tyr(845) of the EGFR. Ipriflavone does not promote apoptosis of MDA-231 cells[1]. Ipriflavone also promotes the deposition of calcium and the formation of mineralized nodules by newborn rat calvarial osteoblast-like cells as well as the activity of alkaline phosphatase[2].
In Vivo:Daily oral administration of ipriflavone at 12 mg/mouse significantly inhibits the development of new osteolytic bone metastases and the progression of established osteolytic lesions, prolonging the life of tumor-bearing mice. Ipriflavone reduces the number of osteoclasts at the bone-cancer interface with no severe adverse effects on the host[1]. 1-month treatment with ipriflavone increases bone density and improves the biomechanical properties of adult rat male bones without altering mineral composition[3]
References:
[1]. Iisaki T, et al. Ipriflavone inhibits osteolytic bone metastasis of human breast cancer cells in a nude mouse model. Int J Cancer. 2002 Aug 1;100(4):381-7.
[2]. Hagiwara H, et al. Ipriflavone down-regulates endothelin receptor levels during differentiation of rat calvarial osteoblast-like cells. J Biochem. 1999 Jul;126(1):168-73.
[3]. Civitelli R, et al. Ipriflavone improves bone density and biomechanical properties of adult male rat bones. Calcif Tissue Int. 1995 Mar;56(3):215-9.
- 4,5-Dimethoxy-1-cyanobenzocyclobutane
Catalog No.:BCC8665
CAS No.:35202-54-1
- AY-NH2
Catalog No.:BCC3949
CAS No.:352017-71-1
- JC-1
Catalog No.:BCC1669
CAS No.:3520-43-2
- D-Tetrahydropalmatine
Catalog No.:BCN2334
CAS No.:3520-14-7
- INCA-6
Catalog No.:BCC2462
CAS No.:3519-82-2
- Isopropylidenylacetyl-marmesin
Catalog No.:BCN6792
CAS No.:35178-20-2
- 5-Nonadecylresorcinol
Catalog No.:BCN7629
CAS No.:35176-46-6
- Deacylmetaplexigenin
Catalog No.:BCC8163
CAS No.:3513-04-0
- Blasticidin S HCl
Catalog No.:BCC5565
CAS No.:3513-03-9
- GNTI dihydrochloride
Catalog No.:BCC7003
CAS No.:351183-88-5
- Adynerin
Catalog No.:BCN4643
CAS No.:35109-93-4
- H-D-His-OH
Catalog No.:BCC2959
CAS No.:351-50-8
- Neobyakangelicol
Catalog No.:BCN5288
CAS No.:35214-82-5
- Alloisoimperatorin
Catalog No.:BCN6789
CAS No.:35214-83-6
- 4-(Bromomethyl)-7-methoxy coumarin
Catalog No.:BCC9202
CAS No.:35231-44-8
- Benzoin methyl ether
Catalog No.:BCC8857
CAS No.:3524-62-7
- 9-Methoxy-alpha-lapachone
Catalog No.:BCN5289
CAS No.:35241-80-6
- Delafloxacin meglumine
Catalog No.:BCC1523
CAS No.:352458-37-8
- Caesalmin B
Catalog No.:BCN7252
CAS No.:352658-23-2
- 1-Chloroindan
Catalog No.:BCN2244
CAS No.:35275-62-8
- Ziyuglycoside I
Catalog No.:BCN5290
CAS No.:35286-58-9
- Ziyuglycoside II
Catalog No.:BCN5291
CAS No.:35286-59-0
- (E)-3-Hydroxy-5-methoxystilbene
Catalog No.:BCN5292
CAS No.:35302-70-6
- D-Alaninol
Catalog No.:BCC2728
CAS No.:35320-23-1
Pharmacokinetics of ipriflavone and metabolites after oral administration of a corn-oil suspension relative to the Osteofix tablet.[Pubmed:10423615]
Am J Ther. 1997 Jul-Aug;4(7-8):229-38.
Ipriflavone (IP) is a derivative of naturally occurring isoflavones and is marketed as Osteofix for the treatment of osteoporosis in Europe. IP has poor aqueous solubility, and the Osteofix compressed tablet has poor and variable bioavailability (F ). IP is incompletely absorbed after oral administration and is converted to five major metabolites (M1, M2, M3, M4, and M5). It is also further converted to metabolites M6 and M7 to a very small extent. The metabolites, especially M2 and M5, also have activity. A pilot study was conducted in healthy male volunteers that showed an 8- to 20-fold increase in the IP bioavailability after administration of Osteofix tablets in the fed state relative to the fasting state. A four-way crossover study was conducted in 16 healthy male volunteers, receiving Osteofix in fed state and 50, 100, and 200 mg of IP corn-oil suspension in fasted state. All IP administrations were safe and well tolerated. There was a reduction in the IP plasma level variability after 100-mg corn-oil administration as compared with that for the tablet. There was an increased relative F after the suspension, which was such that the 50-mg IP corn-oil suspension yielded similar levels as the 200-mg tablet. M5 was the major metabolite, consistent with earlier reports. The area under the curve to the last measured time point (AUC ( t ) ) levels were lower for M5, M3, and M2; higher for M1 and M2; and similar for IP after 50-mg corn-oil administration, as compared with the values for the tablet. This result may partially be explained by differences in the half-lives. Absorption/formation of M2 was delayed. The metabolite formation, except for M1 and M5, decreased with increased doses, which was accompanied by the prolonged half-life of IP and nonproportional increase in the IP AUC ( t ). This result may be due to autoinhibition of IP metabolism, because IP is an inhibitor of CYP3A4, and the metabolism of IP may be partly CYP3A4 mediated. Osteofix F may be improved by formulations that increase solubility, such as the corn-oil suspension. Although equivalent IP exposure from the tablet may be achieved at much lower overall doses because of the improved F by the corn-oil suspension, higher doses may require reconfirmation of safety and efficacy, given the differences in metabolic profiles obtained at higher doses.